Menu
Search
|

Menu

Close
X

Neurocrine Biosciences Inc NBIX.OQ (NASDAQ Stock Exchange Global Select Market)

103.22 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 103.22
Open --
Volume --
3m Avg Volume 252,882
Today’s High --
Today’s Low --
52 Week High 106.26
52 Week Low 46.13
Shares Outstanding (mil) 88.22
Market Capitalization (mil) 5,508.56
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
71
FY17
162
FY16
15
FY15
20
EPS (USD)
FY18
-0.467
FY17
-1.627
FY16
-1.626
FY15
-1.037
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
869.54
5.73
Price to Book (MRQ)
vs sector
15.95
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
104.47
16.84
LT Debt to Equity (MRQ)
vs sector
104.47
12.51
Return on Investment (TTM)
vs sector
-38.94
14.61
Return on Equity (TTM)
vs sector
-60.54
16.34

EXECUTIVE LEADERSHIP

William Rastetter
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Kevin Gorman
Chief Executive Officer, Director, Since 2017
Salary: $575,000.00
Bonus: $345,000.00
Matthew Abernethy
Chief Financial Officer, Since 2017
Salary: $38,231.00
Bonus: $20,071.00
Eric Benevich
Chief Commercial Officer, Since 2015
Salary: $218,532.00
Bonus: $109,300.00
Haig Bozigian
Chief Development Officer, Since 2012
Salary: $381,600.00
Bonus: $190,800.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

12780 El Camino Real
SAN DIEGO   CA   92130-2042

Phone: +1858.6177600

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

SPONSORED STORIES